Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Neurology

Topics

Medicine

Pathology

Internal Medicine

Neurology

Infectious Diseases

Show all topics

DOI

10.1016/s1474-4422(21)00159-9

Other Formats

PDF